CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
7.40
4.52%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 7.08
Open* 7.24
1-Year Change* 53.07%
Day's Range* 7.16 - 7.66
52 wk Range 4.90-100.17
Average Volume (10 days) 312.08K
Average Volume (3 months) 8.16M
Market Cap 386.57M
P/E Ratio -100.00K
Shares Outstanding 52.31M
Revenue N/A
EPS -6.84
Dividend (Yield %) N/A
Beta 1.79
Next Earnings Date Feb 27, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 27, 2024 7.40 0.35 4.96% 7.05 7.75 7.05
Mar 26, 2024 7.08 1.05 17.41% 6.03 7.14 6.03
Mar 25, 2024 6.10 -0.07 -1.13% 6.17 6.61 6.01
Mar 22, 2024 6.22 0.52 9.12% 5.70 6.49 5.69
Mar 21, 2024 5.72 -0.02 -0.35% 5.74 5.98 5.45
Mar 20, 2024 5.76 0.64 12.50% 5.12 5.88 4.89
Mar 19, 2024 5.32 -0.17 -3.10% 5.49 5.81 5.29
Mar 18, 2024 5.66 -0.18 -3.08% 5.84 5.97 5.55
Mar 15, 2024 5.83 0.21 3.74% 5.62 5.86 5.47
Mar 14, 2024 5.60 -0.49 -8.05% 6.09 6.28 5.54
Mar 13, 2024 6.30 0.52 9.00% 5.78 6.32 5.78
Mar 12, 2024 5.91 0.08 1.37% 5.83 6.03 5.64
Mar 11, 2024 5.87 -0.16 -2.65% 6.03 6.30 5.80
Mar 8, 2024 6.15 0.01 0.16% 6.14 6.58 6.07
Mar 7, 2024 6.18 0.35 6.00% 5.83 6.20 5.70
Mar 6, 2024 5.90 0.04 0.68% 5.86 6.17 5.64
Mar 5, 2024 5.83 0.07 1.22% 5.76 6.47 5.73
Mar 4, 2024 5.92 -0.06 -1.00% 5.98 6.00 5.36
Mar 1, 2024 5.99 0.07 1.18% 5.92 6.24 5.89
Feb 29, 2024 5.98 0.15 2.57% 5.83 6.17 5.83

Kodiak Sciences Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 341.379 267.051 136.007 49.19 31.853
Selling/General/Admin. Expenses, Total 73.788 49.711 28.618 11.684 7.581
Research & Development 267.591 217.34 107.389 37.506 18.793
Operating Income -341.379 -267.051 -136.007 -49.19 -31.853
Interest Income (Expense), Net Non-Operating 7.053 0.276 2.877 1.56 -3.531
Other, Net 0.503 -0.215 0.034 0.265 -6.059
Net Income Before Taxes -333.823 -266.99 -133.096 -47.365 -41.443
Net Income After Taxes -333.823 -266.99 -133.096 -47.365 -41.443
Net Income Before Extra. Items -333.823 -266.99 -133.096 -47.365 -41.443
Net Income -333.823 -266.99 -133.096 -47.365 -41.443
Income Available to Common Excl. Extra. Items -333.823 -266.99 -133.096 -47.365 -41.443
Income Available to Common Incl. Extra. Items -333.823 -266.99 -133.096 -47.365 -41.443
Diluted Net Income -333.823 -266.99 -133.096 -47.365 -41.443
Diluted Weighted Average Shares 52.2496 51.7889 45.7419 37.8536 36.9099
Diluted EPS Excluding Extraordinary Items -6.389 -5.15535 -2.90972 -1.25127 -1.12282
Dividends per Share - Common Stock Primary Issue
Diluted Normalized EPS -6.389 -5.15535 -2.90972 -1.25127 -0.97437
Unusual Expense (Income) 0 5.479
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 84.832 74.615 74.066 79.478 92.068
Selling/General/Admin. Expenses, Total 17.871 18.095 18.072 17.802 18.324
Research & Development 66.961 56.52 55.994 61.676 73.744
Operating Income -84.832 -74.615 -74.066 -79.478 -92.068
Interest Income (Expense), Net Non-Operating 4.679 3.613 3.828 2.024 1.13
Other, Net -0.035 0.222 -0.21 0.416 0.31
Net Income Before Taxes -80.188 -70.78 -70.448 -77.038 -90.628
Net Income After Taxes -80.188 -70.78 -70.448 -77.038 -90.628
Net Income Before Extra. Items -80.188 -70.78 -70.448 -77.038 -90.628
Net Income -80.188 -70.78 -70.448 -77.038 -90.628
Income Available to Common Excl. Extra. Items -80.188 -70.78 -70.448 -77.038 -90.628
Income Available to Common Incl. Extra. Items -80.188 -70.78 -70.448 -77.038 -90.628
Diluted Net Income -80.188 -70.78 -70.448 -77.038 -90.628
Diluted Weighted Average Shares 52.3787 52.3376 52.3173 52.2883 52.2188
Diluted EPS Excluding Extraordinary Items -1.53093 -1.35237 -1.34655 -1.47333 -1.73554
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.53093 -1.35237 -1.34655 -1.47333 -1.73554
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 486.005 734.811 972.005 339.23 90.449
Cash and Short Term Investments 478.933 731.51 968.974 336.481 88.254
Cash & Equivalents 190.433 731.51 944.396 211.797 88.254
Prepaid Expenses 7.072 3.301 3.031 2.749 2.195
Total Assets 666.628 904.22 1067.35 358.866 92.189
Property/Plant/Equipment, Total - Net 115.753 108.074 78.808 2.786 1.097
Property/Plant/Equipment, Total - Gross 122.477 111.013 80.978 4.557 2.782
Accumulated Depreciation, Total -6.724 -2.939 -2.17 -1.771 -1.685
Other Long Term Assets, Total 64.87 61.335 16.534 5.154 0.643
Total Current Liabilities 52.496 64.683 31.422 11.711 4.826
Accounts Payable 9.13 12.431 8.646 2.619 1.05
Accrued Expenses 43.366 52.252 22.776 9.092 3.776
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases
Other Current Liabilities, Total
Total Liabilities 230.461 240.9 206.596 13.507 5.356
Total Long Term Debt 0 0 0 0 0
Long Term Debt 0
Capital Lease Obligations
Other Liabilities, Total 177.965 176.217 175.174 1.796 0.53
Total Equity 436.167 663.32 860.751 345.359 86.833
Preferred Stock - Non Redeemable, Net 0
Common Stock 0.005 0.005 0.005 0.005 0.004
Additional Paid-In Capital 1329.51 1221.53 1151.92 503.475 197.595
Retained Earnings (Accumulated Deficit) -892.04 -558.217 -291.227 -158.131 -110.766
Total Liabilities & Shareholders’ Equity 666.628 904.22 1067.35 358.866 92.189
Total Common Shares Outstanding 52.3339 51.8263 51.1123 44.4134 36.8299
Short Term Investments 288.5 0 24.578 124.684
Long Term Investments 0 0 11.696
Redeemable Preferred Stock 0 0 0 0
Other Equity, Total -1.307 0 0.053 0.01
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 350.927 386.959 431.118 486.005 544.662
Cash and Short Term Investments 345.668 378.67 421.191 478.933 537.395
Cash & Equivalents 345.668 378.67 316.615 190.433 178.413
Short Term Investments 0 0 104.576 288.5 358.982
Prepaid Expenses 5.259 8.289 9.927 7.072 7.267
Total Assets 547.652 589.659 640.334 666.628 723.988
Property/Plant/Equipment, Total - Net 181.669 187.372 193.695 115.753 117.361
Long Term Investments
Other Long Term Assets, Total 15.056 15.328 15.521 64.87 61.965
Total Current Liabilities 70.774 74.242 68.938 52.496 65.6
Accounts Payable 38.589 12.347 6.262 9.13 15.607
Accrued Expenses 32.185 61.895 62.676 43.366 49.993
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 245.235 251.181 247.747 230.461 244.459
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 174.461 176.939 178.809 177.965 178.859
Total Equity 302.417 338.478 392.587 436.167 479.529
Redeemable Preferred Stock 0 0 0 0
Common Stock 0.005 0.005 0.005 0.005 0.005
Additional Paid-In Capital 1395.43 1381.48 1355.5 1329.51 1303.62
Retained Earnings (Accumulated Deficit) -1093.02 -1043.01 -962.82 -892.04 -821.592
Other Equity, Total 0 0 -0.096 -1.307 -2.505
Total Liabilities & Shareholders’ Equity 547.652 589.659 640.334 666.628 723.988
Total Common Shares Outstanding 52.4673 52.4532 52.3447 52.3339 52.3041
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -333.823 -266.99 -133.096 -47.365 -41.443
Cash From Operating Activities -206.459 -182.27 -83.428 -39.146 -29.031
Cash From Operating Activities 3.796 1.003 0.477 0.538 0.49
Non-Cash Items 111.607 69.291 34.397 6.242 18.314
Cash Interest Paid 0.018 0.022 0.025 0.008 0.019
Changes in Working Capital 11.961 14.426 14.794 1.439 -6.392
Cash From Investing Activities -336.513 -38.798 104.834 -136.998 -0.581
Capital Expenditures -47.363 -63.298 -6.998 -0.437 -0.581
Cash From Financing Activities 1.895 8.182 717.377 299.687 116.471
Financing Cash Flow Items -0.049 -0.045 99.118 -0.168 -0.225
Issuance (Retirement) of Stock, Net 1.944 8.227 618.264 299.903 83.804
Issuance (Retirement) of Debt, Net 0 0 -0.005 -0.048 32.892
Net Change in Cash -541.077 -212.886 738.783 123.543 86.859
Other Investing Cash Flow Items, Total -289.15 24.5 111.832 -136.561
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -70.78 -333.823 -263.375 -186.337 -95.709
Cash From Operating Activities -47.221 -206.459 -151.384 -98.297 -43.16
Cash From Operating Activities 3.81 3.796 2.234 1.075 0.298
Non-Cash Items 27.312 111.607 85.004 57.527 30.012
Changes in Working Capital -7.563 11.961 24.753 29.438 22.239
Cash From Investing Activities 173.406 -336.513 -403.511 -462.241 -18.289
Capital Expenditures -12.247 -47.363 -41.745 -34.475 -18.289
Other Investing Cash Flow Items, Total 185.653 -289.15 -361.766 -427.766 0
Cash From Financing Activities -0.003 1.895 1.798 1.72 1.666
Financing Cash Flow Items -0.012 -0.049 -0.036 -0.024 -0.012
Issuance (Retirement) of Stock, Net 0.009 1.944 1.834 1.744 1.678
Issuance (Retirement) of Debt, Net 0
Net Change in Cash 126.182 -541.077 -553.097 -558.818 -59.783

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Kodiak Sciences Inc. Company profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat retinal diseases. The company''s lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidate include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases. The company''s early research pipeline include KSI-601, a triplet inhibitor for dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
Industry: Bio Therapeutic Drugs

1200 Page Mill Rd
PALO ALTO
CALIFORNIA 94304
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

ETH/USD

3,577.48 Price
+1.800% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

Gold

2,194.93 Price
0.000% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.30

XRP/USD

0.63 Price
+1.240% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

BTC/USD

70,387.95 Price
+2.130% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading